cardiovascular outcome
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
... CVD: cardiovascular disease; CVOT: cardiovascular outcome trial; DIGAMI: diabetes and insulin-glucose infusion in acute myocardial infarction; DPP4: dipeptydil peptidase 4; EASD: European Association ...
11
Updates on cardiovascular outcome trials in diabetes
... & cardiovascular disease; EASD: European Association for the Study of Diabetes; CV: cardiovascular; CVD: cardiovascular disease; FDA: Food and Drug Administration; EMA: European medicine agency; ...
13
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
... from cardiovascular disease (CVD), which accounts for ...mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the ...for Cardiovascular Risk, Outcomes and Safety ...
8
Cardiovascular outcome trials of diabetes drugs: lessons learned
... recent cardiovascular outcome studies as evidence in favor of selecting specific drugs ...erosclerotic cardiovascular disease ...these cardiovascular outcome studies demonstrated ...
5
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
... between the treatment and placebo groups in the EXAM- INE [19, 20] and HARMONY [24] trials, whereas it was lower in the sitagliptin group in the TECOS trial [23]. The urinary albumin-to-creatinine ratio (UACR) showed ...
8
Report from the 5th cardiovascular outcome trial (CVOT) summit
... adverse cardiovascular event; ACE: Angiotensin-converting-enzyme; ARB: Angiotensin-receptor blocker; ASCVD: Atherosclerotic cardiovascular disease; CHD: Coronary heart disease; CI: Confidence interval; CKD: ...
10
PDM-ProValue meets cardiovascular outcome trials in diabetes
... Novel studies have increased our knowledge regarding optimal treatment options in diabetes. Key studies that have broadened our knowledge about optimal treatment options in diabetes in recent years are ...
7
Current perspectives on cardiovascular outcome trials in diabetes
... complications, cardiovascular disease (CVD) stands as the leading cause for mortal- ity and adverse outcomes in patients with type 2 diabe- tes ...large-scale cardiovascular outcome trials ...
12
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
... CV: cardiovascular; CVD: cardiovascular disease; CVOT: cardiovascular outcome trials; D&CVD: Diabetes and Cardiovascular Disease; EASD: European Associa- tion of the Study of ...
6
Distress related to myocardial infarction and cardiovascular outcome: a retrospective observational study
... Data were analyzed using SPSS 15.0 statistical software package (SPSS Inc. Chicago, IL). Two-tailed level of sig- nificance was set at p < 0.05. Differences between groups were calculated using Student’s t test, ...
8
<p>Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials</p>
... 51. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. 52. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure ...
9
Managing cardiovascular risk in type 2 diabetes: what do the cardiovascular outcome trials mean for Australian practice?
... EMPA-REG OUTCOME cohort) and, unlike canagliflozin and empagliflozin, resulted in a non-significant reduction in the co-primary end point of MACE (Table 4) ...
19
Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance
... 18-month outcome data from this study are parti- cularly interesting and highlight an important message regarding risk stratification of AMI ...worse outcome than those with ...
10
Cardiovascular outcome associations among cardiovascular magnetic resonance measures of arterial stiffness: the Dallas heart study
... While assessment of arterial stiffness is suggested to improve risk stratification as a measure of end-organ disease [34], it is important to note that susceptibility to insult from cardiovascular risk factors ...
9
Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events
... Cardiovascular outcome trials (CVOT) [1–3], con- ducted at almost glucose equipoise in patients with type 2 diabetes mellitus (T2D), have shown that, in patients with established atherosclerotic ...
15
Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney
... Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 ...
6
Glucagon and heart in type 2 diabetes: new perspectives
... The cardiovascular outcome trials, requested by the FDA, raised some concerns about the possibility that the dipeptidyl peptidase-4 inhibitors can precipitate the heart failure, while, at least for ...
7
1-s2.0-S0002870316300904-main.pdf
... comparator-controlled cardiovascular outcomes trial, designed as an event-driven trial that would continue until at least 633 positively adjudicated, primary cardiovascular outcome events were ...
9
Clinical Presentations and Outcome of Cardiovascular Emergencies in Yaounde: A Cross Sectional Study
... gated, and under treated [9] [21]. Access to diagnostic tests and essential medi- cines remain very low [22]. This low rate of awareness and undertreatment will often translate as a cardiovascular emergency. The ...
10
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
... ongoing Cardiovascular and Renal Microvascular Outcome study with Linagliptin in patients with T2DM (CARMELINA), which is pow- ered to evaluate kidney outcomes and renoprotective effects of this inhibitor, ...
15